<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00119639</url>
  </required_header>
  <id_info>
    <org_study_id>11804</org_study_id>
    <nct_id>NCT00119639</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of BAY 43-9006</brief_title>
  <official_title>A Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of Sorafenib (BAY 43-9006, Nexavar).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <brief_summary>
    <textblock>
      This is a 400 mg (2 x 200 mg tablets) sorafenib single dose, open-label study being conducted&#xD;
      to compare the pharmacokinetics of plasma and urine and safety of sorafenib in subjects with&#xD;
      severe, moderate, and mild renal impairment with those exhibiting normal renal function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of sorafenib in plasma and urine; single-dose safety of sorafenib in patients with renal impairment</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib (BAY43-9006, Nexavar)</intervention_name>
    <description>All subjects were given a open-label, single dose of 400mg sorafenib</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Post menopausal females&#xD;
&#xD;
          -  Surgically sterile females&#xD;
&#xD;
          -  Body Mass Index between 18-37&#xD;
&#xD;
          -  Subjects with Clcr greater than 80 mL/min&#xD;
&#xD;
          -  Subjects with Clcr 50 to 80 mL/min&#xD;
&#xD;
          -  Subjects with Clcr 30 to 50 mL/min&#xD;
&#xD;
          -  Clcr less than 30 mL/min but not on dialysis&#xD;
&#xD;
          -  Subjects must test negative for HIV&#xD;
&#xD;
          -  Subjects must test negative for drugs of abuse at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All Subjects :&#xD;
&#xD;
          -  Concomitant Medication: Treatment with CYP3A4 inducers, such as rifampin and St.&#xD;
             John's Wort within 14 days of Day 1 until they leave the clinic on Day 7&#xD;
&#xD;
          -  Donation of blood within 30 days of Day 1&#xD;
&#xD;
          -  Recent participation in an investigational drug study during which active medication&#xD;
             was given within 30 days of Day 1&#xD;
&#xD;
          -  History of gastrointestinal disorder that could result in incomplete absorption of&#xD;
             study drug&#xD;
&#xD;
          -  Malignancy&#xD;
&#xD;
          -  Significant neurologic or psychiatric disorders&#xD;
&#xD;
          -  History of drug or alcohol abuse in year prior to screening for this trial, or current&#xD;
             intake or &gt;14 standard alcoholic drinks per week&#xD;
&#xD;
          -  Prior history of epilepsy or other seizure disorders&#xD;
&#xD;
          -  Known hypersensitivity to inhibitors of raf kinase or VEGFR-2&#xD;
&#xD;
          -  Females of child-bearing potential&#xD;
&#xD;
          -  Smoking &gt; 10 cigarettes/day or equivalent&#xD;
&#xD;
          -  Excessive consumption (more than five 8-oz. cups/day) of coffee or caffeine&#xD;
&#xD;
        Healthy Volunteer:&#xD;
&#xD;
          -  Existing failure of a major organ system, or a medical disorder that would impair the&#xD;
             subject's ability to complete the study (in the opinion of the investigator or the&#xD;
             sponsor), eg history of blood coagulation disorders&#xD;
&#xD;
          -  Hematocrit value &lt; 34% in the control group at screening&#xD;
&#xD;
        Renal Impairment Groups:&#xD;
&#xD;
          -  Existing failure of a major organ system or a medical disorder (other than the target&#xD;
             disease) which would impair the subject's ability to complete the study (in the&#xD;
             opinion of the investigator or the sponsor)&#xD;
&#xD;
          -  Concomitant Medication: Renal impairment subjects taking phosphate binders, ion&#xD;
             exchange resins and/or iron supplements may take them with their meals, but must&#xD;
             withhold them on the morning of Day 1 (dosing day) until after their 4 hour post-dose&#xD;
             tests and procedures are performed.&#xD;
&#xD;
          -  Myocardial infarction, coronary artery bypass graft or percutaneous transluminal&#xD;
             coronary angiography within 6 months of Day 1; unstable angina; uncontrolled&#xD;
             significant hypertension within 3 months of Day 1; cerebral vascular accident or&#xD;
             transient ischemic attack within 12 months of Day 1&#xD;
&#xD;
          -  Subjects with hypertension who have had a medication or dose change within one week of&#xD;
             Day 1&#xD;
&#xD;
          -  Subjects requiring dialysis&#xD;
&#xD;
          -  Subjects with kidney transplants&#xD;
&#xD;
          -  Liver transaminase (AST, ALT) greater than 5 times the ULN at screening; any active&#xD;
             liver disease or unexplained or persistent elevations in liver function tests&#xD;
&#xD;
          -  Hematocrit value &lt; 24% in the renal impaired groups&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>July 8, 2005</study_first_submitted>
  <study_first_submitted_qc>July 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2005</study_first_posted>
  <last_update_submitted>January 15, 2009</last_update_submitted>
  <last_update_submitted_qc>January 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>Head Clinical Pharmacology</name_title>
    <organization>Bayer Healthcare Pharmaceuticals Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

